Apples And Oranges? Not All PI3 Kinase Inhibitors Are Created Equal
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
As development and deal-making activity in the phosphatidyinositol-3-kinase (PI3 kinase) area increases, a crucial question has emerged. Will early investments in pan-selective PI3 kinase inhibitors pay off, or will the more recent focus on isoform-selective compounds prove the better approach to this space?